home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

2seventy bio, Inc. - Common Stock (NQ:TSVT)

5.000 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

February 27, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

Via Newsfile

2seventy bio to Participate in Upcoming Investor Conferences

February 05, 2024

From 2seventy bio, Inc.

Via Business Wire

Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

February 05, 2024

From Bristol Myers Squibb

Via Business Wire

2seventy bio: Q3 Earnings Insights ↗

November 14, 2023

Via Benzinga

Preview: 2seventy bio's Earnings ↗

November 13, 2023

Via Benzinga

Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? ↗

February 02, 2024

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.

Via Benzinga

Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 31, 2024

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 31, 2024

Via Benzinga

Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results ↗

January 31, 2024

U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling more than 200 points on Wednesday. The Dow traded up 0.08% to 38,497.13 while the NASDAQ fell 1.41% to...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 30, 2024

Via Benzinga

2seventy bio Announces New Strategic Path Forward

January 30, 2024

From 2seventy bio, Inc.

Via Business Wire

Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion ↗

January 07, 2024

Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...

Via Talk Markets

Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December ↗

December 19, 2023

Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &...

Via Benzinga

Topics ETFs

Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

December 11, 2023

From Bristol Myers Squibb

Via Business Wire

2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)

December 11, 2023

From 2seventy bio, Inc.

Via Business Wire

2seventy bio Reiterates Commitment to Maximizing Shareholder Value

December 06, 2023

From 2seventy bio, Inc.

Via Business Wire

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗

November 29, 2023

Tuesday, the FDA said it received reports of patients developing T-cell malig

Via Benzinga

Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today? ↗

November 20, 2023

Shares of Bristol-Myers Squibb Company (NYSE: BMY) and 2seventy Bio Inc (NASDAQ: TSVT) fell after the companies' efforts to win expanded U.S.

Via Benzinga

Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 20, 2023

Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...

Via Benzinga

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

November 20, 2023

From Bristol Myers Squibb

Via Business Wire

3 Biotech Stocks With Key Catalysts Coming in December ↗

November 15, 2023

Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.

Via InvestorPlace

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

November 14, 2023

From 2seventy bio, Inc.

Via Business Wire

2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023

November 10, 2023

From 2seventy bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 26, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023 ↗

October 12, 2023

Via Benzinga

2 Growth Stocks That Could Rocket Higher Before the End of 2023 ↗

October 08, 2023

Potential approvals of new medicines expected soon could push these stocks through the roof.

Via The Motley Fool

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy ↗

September 16, 2023

Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...

Via Talk Markets

Stocks That Hit 52-Week Lows On Thursday ↗

September 21, 2023

During the session on Thursday, 461 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

September 19, 2023

During Tuesday's session, 275 companies made new 52-week lows.

Via Benzinga

Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 15, 2023

Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com